Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dominick, M. A.
Right arrow Articles by Gough, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dominick, M. A.
Right arrow Articles by Gough, A. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Morphogenesis of a Zone-Specific Adrenocortical Cytotoxicity in Guinea Pigs Administered PD 132301-2, an Inhibitor of Acyl-CoA: Cholesterol Acyltransferase

Mark A. Dominick

Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105

Walter A. Bobrowski

Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105

John R. Macdonald

Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105

Alec W. Gough

Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105

PD 132301-2, a novel inhibitor of acyl-CoA: cholesterol acyltransferase, is adrenotoxic to several laboratory animal species. Morphogenesis of a zona fasciculata-specific cytotoxicity was evaluated in male Hartley guinea pigs administered 100 mg/kg of PD 132301–2 for up to 7 days. Reversibility of adrenal effects was assessed after a 14-day drug withdrawal period (day 21). Serum Cortisol concentrations were determined under basal conditions and after administration of adrenocorticotrophic hormone (ACTH) on days 1, 2, 4, 7, and 21. Isolated foci of cortical cell degeneration and necrosis were apparent in outer zona fasciculata by 2 hr and throughout the zona fasciculata at 6 hr. Early degenerative ultrastructural changes included aggregation of smooth endoplasmic reticulum (SER), variable condensation of mitochondrial matrices and swelling of cristae, partitioning of organelles, autophagosome formation, and disruption of lipid globules. Lesions progressed to locally extensive or diffuse zonal necrosis on days 1 and 2 and near complete ablation of zona fasciculata by day 4. Fasciculata cells remaining on day 4 had reduced numbers and increased size of lipid globules, increased lysosomes, and, occasionally, aggregates of SER and mitochondria. On day 7, SER proliferation and lipid depletion were apparent in remaining cells. ACTH responses were attenuated 24 hr after the first dose, and reduction in basal Cortisol levels were seen by 24 hr after the second dose with both effects maximal on day 7. After a 14-day withdrawal period, ACTH responses and adrenal morphology returned to normal. It was concluded that PD 132301–2 induced rapid, reversible, zone-specific, morphologic, and functional adrenocortical effects. Furthermore, mitochondria and SER represented early subcellular targets of toxicity.

Key Words: Adrenotoxicity • acyl-CoA • cholesterol acyltransferase inhibitor • zona fasciculata • ultrastructural lesion • mitochondria • smooth endoplasmic reticulum • ACTH response

Toxicologic Pathology, Vol. 21, No. 1, 54-62 (1993)
DOI: 10.1177/019262339302100107


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. V. Farese Jr
The Nine Lives of ACAT Inhibitors
Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1684 - 1686.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Hori, M. Satoh, K. Furukawa, Y.-i. Sakamoto, H. Hakamata, Y. Komohara, M. Takeya, Y. Sasaki, A. Miyazaki, and S. Horiuchi
Acyl-Coenzyme A:Cholesterol Acyltransferase-2 (ACAT-2) Is Responsible for Elevated Intestinal ACAT Activity in Diabetic Rats
Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1689 - 1695.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
K. Kaneko, K. Uchida, T. Kobayashi, K. Miura, K. Tanokura, K. Hoshino, I. Kato, M. Onoue, and T. Yokokura
Sex-Dependent Toxicity of a Novel Acyl-CoA:Cholesterol Acyltransferase Inhibitor, YIC-C8-434, in Relation to Sex-Specific Forms of Cytochrome P450 in Rats
Toxicol. Sci., December 1, 2001; 64(2): 259 - 268.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
D. G. Robertson, M. A. Breider, and M. A. Milad
Preclinical Safety Evaluation of Avasimibe in Beagle Dogs: An ACAT Inhibitor with Minimal Adrenal Effects
Toxicol. Sci., February 1, 2001; 59(2): 324 - 334.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Cases, S. Novak, Y.-W. Zheng, H. M. Myers, S. R. Lear, E. Sande, C. B. Welch, A. J. Lusis, T. A. Spencer, B. R. Krause, et al.
ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase. ITS CLONING, EXPRESSION, AND CHARACTERIZATION
J. Biol. Chem., October 9, 1998; 273(41): 26755 - 26764.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
I. Ishii, N. Yokoyama, M. Yanagimachi, N. Ashikawa, M. Hata, S. Murakami, Y. Asami, N. Morisaki, Y. Saito, S. Ohmori, et al.
Stimulation of Cholesterol Release from Rabbit Foam Cells by the Action of a New Inhibitor for Acyl CoA:Cholesterol Acyltransferase (ACAT), HL-004
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 115 - 121.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
V. L. Meiner, S. Cases, H. M. Myers, E. R. Sande, S. Bellosta, M. Schambelan, R. E. Pitas, J. McGuire, J. Herz, and R. V. Farese Jr.
Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals
PNAS, November 26, 1996; 93(24): 14041 - 14046.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. J. Warner, G. Stoudt, M. Bamberger, W. J. Johnson, and G. H. Rothblat
Cell Toxicity Induced by Inhibition of Acyl Coenzyme A:Cholesterol Acyltransferase and Accumulation of Unesterified Cholesterol
J. Biol. Chem., March 17, 1995; 270(11): 5772 - 5778.
[Abstract] [Full Text] [PDF]